Analysts expect Eyenovia Inc (NASDAQ:EYEN) to report earnings per share of ($0.39) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Eyenovia’s earnings. The firm is scheduled to issue its next earnings results on Wednesday, August 8th.
On average, analysts expect that Eyenovia will report full-year earnings of ($1.87) per share for the current fiscal year, with EPS estimates ranging from ($1.97) to ($1.77). For the next fiscal year, analysts forecast that the company will post earnings of ($1.71) per share, with EPS estimates ranging from ($1.80) to ($1.62). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Eyenovia.
Eyenovia (NASDAQ:EYEN) last announced its quarterly earnings data on Wednesday, May 9th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06).
Eyenovia stock traded down $0.07 during trading hours on Friday, hitting $7.96. The stock had a trading volume of 22,346 shares, compared to its average volume of 10,691. The company has a market capitalization of $79.79 million and a PE ratio of -3.63. Eyenovia has a one year low of $7.32 and a one year high of $10.74.
Institutional investors have recently bought and sold shares of the business. Sabby Management LLC bought a new position in Eyenovia in the first quarter valued at about $908,000. Uniplan Investment Counsel Inc. bought a new position in Eyenovia in the first quarter valued at about $3,248,000. Highbridge Capital Management LLC bought a new position in Eyenovia in the first quarter valued at about $1,373,000. Finally, Millennium Management LLC bought a new position in Eyenovia in the first quarter valued at about $2,525,000. Hedge funds and other institutional investors own 12.46% of the company’s stock.
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst that has completed Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat that has completed Phase II clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.